Mankind Pharmaceuticals inks licensing pact with Glenmark Pharmaceuticals

23 Dec 2019 Evaluate

Mankind Pharmaceuticals has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country. Under the sub-licensing agreement, Mankind will market the drug under its own trademark while Glenmark will manufacture and supply it to the drug firm.

This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen Mankind Pharma’s diabetes portfolio but also help consolidate its position as the fastest-growing player in the anti-diabetes segment.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharma Share Price

1030.05 -6.10 (-0.59%)
22-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1540.30
Dr. Reddys Lab 5872.65
Cipla 1481.55
Zydus Lifesciences 1076.45
Lupin 1712.05
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.